X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs WOCKHARDT LTD. - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA WOCKHARDT LTD. TORRENT PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 27.9 -15.2 - View Chart
P/BV x 5.3 2.5 212.5% View Chart
Dividend Yield % 1.0 1.3 77.7%  

Financials

 TORRENT PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
WOCKHARDT LTD.
Mar-17
TORRENT PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1,7681,129 156.6%   
Low Rs1,186627 189.1%   
Sales per share (Unadj.) Rs346.1363.1 95.3%  
Earnings per share (Unadj.) Rs55.2-20.4 -269.8%  
Cash flow per share (Unadj.) Rs73.3-7.0 -1,051.0%  
Dividends per share (Unadj.) Rs14.0010.00 140.0%  
Dividend yield (eoy) %0.91.1 83.2%  
Book value per share (Unadj.) Rs257.1301.8 85.2%  
Shares outstanding (eoy) m169.22110.55 153.1%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.32.4 176.5%   
Avg P/E ratio x26.8-42.9 -62.3%  
P/CF ratio (eoy) x20.1-125.9 -16.0%  
Price / Book Value ratio x5.72.9 197.5%  
Dividend payout %25.4-48.9 -51.9%   
Avg Mkt Cap Rs m249,88797,063 257.4%   
No. of employees `00011.86.8 174.1%   
Total wages/salary Rs m9,9349,665 102.8%   
Avg. sales/employee Rs Th4,971.55,931.8 83.8%   
Avg. wages/employee Rs Th843.21,428.1 59.0%   
Avg. net profit/employee Rs Th792.4-334.0 -237.3%   
INCOME DATA
Net Sales Rs m58,56940,146 145.9%  
Other income Rs m2,2331,143 195.4%   
Total revenues Rs m60,80241,289 147.3%   
Gross profit Rs m13,773128 10,759.9%  
Depreciation Rs m3,0691,489 206.1%   
Interest Rs m2,0562,253 91.3%   
Profit before tax Rs m10,881-2,472 -440.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,545-211 -731.9%   
Profit after tax Rs m9,336-2,260 -413.0%  
Gross profit margin %23.50.3 7,375.4%  
Effective tax rate %14.28.5 166.3%   
Net profit margin %15.9-5.6 -283.1%  
BALANCE SHEET DATA
Current assets Rs m53,84146,160 116.6%   
Current liabilities Rs m31,61219,258 164.1%   
Net working cap to sales %38.067.0 56.6%  
Current ratio x1.72.4 71.1%  
Inventory Days Days97101 96.5%  
Debtors Days Days8494 89.1%  
Net fixed assets Rs m42,07940,165 104.8%   
Share capital Rs m846553 153.1%   
"Free" reserves Rs m42,65532,814 130.0%   
Net worth Rs m43,50133,367 130.4%   
Long term debt Rs m22,40831,903 70.2%   
Total assets Rs m101,25089,687 112.9%  
Interest coverage x6.3-0.1 -6,479.4%   
Debt to equity ratio x0.51.0 53.9%  
Sales to assets ratio x0.60.4 129.2%   
Return on assets %11.30 -131,045.1%  
Return on equity %21.5-6.8 -316.8%  
Return on capital %19.6-0.3 -5,855.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m20,0669,121 220.0%   
Fx outflow Rs m5,3042,133 248.6%   
Net fx Rs m14,7626,988 211.3%   
CASH FLOW
From Operations Rs m10,127-2,695 -375.8%  
From Investments Rs m-7,869-6,863 114.7%  
From Financial Activity Rs m-1,91812,545 -15.3%  
Net Cashflow Rs m2123,010 7.0%  

Share Holding

Indian Promoters % 71.5 74.5 96.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 2.3 305.2%  
FIIs % 12.6 7.7 163.6%  
ADR/GDR % 0.0 0.1 -  
Free float % 8.8 15.4 57.1%  
Shareholders   26,511 67,757 39.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  ALKEM LABORATORIES  DIVIS LABORATORIES  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 21, 2018 03:35 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS